Table 2.
Clinical parameters of patient cohort.a
| % | |
|---|---|
| Indication | |
| Post-radiotherapy | 50.8 |
| Post-prostatectomy | 22.5 |
| Surgery and radiotherapy | 3 |
| Brachytherapy | 0.7 |
| Hormonal therapy only | 23 |
| Active surveillance/watchful waiting | 0 |
| Gleason score | |
| Well differentiated (≤6) | 15 |
| Moderately differentiated (8) | 65 |
| Poorly differentiated (≥8) | 20 |
| Clinical stage | |
| T1a | 3.5 |
| T1b | 1.5 |
| T1c | 13.6 |
| T2a | 15.2 |
| T2b | 9 |
| T2c | 8.8 |
| T3a | 36.7 |
| T3b | 1.8 |
| T4 | 2.4 |
| Tx | 4.8 |
| Nodal status | |
| N0, N1, N2, Nx | 7.5, 0.9, 0.2, 91.5 |
| Bone metastases | |
| Yes, no, unknown | 7.2, 63.1, 25.3 |
| ECOG status | |
| 1, 2, 3, 4, 5 | 76.7, 19.1, 2.5, 1.2, 0.5 |
| Referred back | |
| PSA rise | 60.8 |
| LUTS | 19.6 |
| DRE concerns | 3.9 |
| Consultant request | 3.9 |
| Active surveillance required | 3.9 |
| Raised creatinine | 3.9 |
| Other raised blood tests | 2 |
| Tight foreskin | 2 |
Abbreviation: DRE, Digital rectal examination; ECOG, Eastern Cooperative Oncology Group; LUTS, lower urinary tract symptoms; PSA, prostate specific antigen.
aN = 815.